Piper Jaffray Cuts Anadys Pharmaceuticals to Underperform
This article is for subscribers only.
From Standard & Poor's Equity Research
Piper Jaffray downgraded Anadys Pharmaceuticals (ANDS) to underperform, citing the news Monday that it has suspended dosing hepatitis C virus (HCV) patients in its ongoing trial of the drug ANA975.